Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone?

Journal of the National Cancer Institute

Volumn 94, Issue 19, 2002, Pages 1422-1423

  Canil, Christina M ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; MITOXANTRONE; PAMIDRONIC ACID; PLACEBO; PREDNISONE; ZOLEDRONIC ACID;

ANEMIA; BONE METASTASIS; BONE PAIN; CANADA; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG USE; EDITORIAL; FATIGUE; FEVER; FRACTURE; HUMAN; LEG EDEMA; MYALGIA; ORTHOPEDIC SURGERY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SPINAL CORD COMPRESSION; STANDARD; SYMPTOM; TREATMENT OUTCOME;

EID: 0037009828     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.19.1422     Document Type: Editorial

References (14)

1. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer 1998;83:1561-6.
2. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335: 1785-91.
3. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999;17:846-54.
4. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002(1):CD003474.
5. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002(3):CD003188.
6. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997;80(8 Suppl): 1674-9.
7. Koizumi M, Yamada Y, Takiguchi T, Nomur E, Furukawa M, Kitahara T, et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 1995;121:542-8.
8. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345: 948-55.
9. Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989;141:85-7.
10. Dearnaley DP, Sydes MR, on behalf of the MRC PR5 Collaborators. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC PR5 Trial. Proc ASCO 2001;20:174a.
11. Ernst DS, Tannock IF, Venner PM, Winquist EW, Reyno L, Walker H, et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc ASCO 2002;21:177a.
12. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
13. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-9.
14. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271-9.